OCGN - Ocugen, Inc. Full Takeover Company Value

Graphic logo of Ocugen Pharma (OCGN)

The asset value of Ocugen, Inc. (OCGN) tracked on this chart is 240.31, highlighting the binary potential for margin growth upon the approval of gene therapy. The business relies on external contractors for drug production and testing, thereby avoiding capital expenditures on manufacturing plants. The firm's environmental profile is limited to basic compliance with waste disposal regulations and office energy efficiency.

Ocugen Pharma (OCGN) - Enterprise Value from 11/23/2025 to 10/30/2026
Flagship merchandise of Ocugen, Inc.

Identifying fundamentally resilient assets requires an analysis of the enterprise value, calculated as the sum of market capitalization and net debt. This metric determines the actual cost of acquiring the Ocugen, Inc. (OCGN) biotech platform and its developments in vaccination and gene therapy, allowing for an assessment of the company's aggregate valuation through the lens of its actual liabilities and liquidity.

Who Ocugen, Inc. competes with

TEM - Real Price to Acquire Entire Company|Qiagen Group - Enterprise Value|Full Takeover Company Value Isis Pharmaceuticals (IONS)|Repligen Corporation (RGEN) - Total Company Value|Business Value RNA|CRSP (CRISPR Therapeutics) - Enterprise Value|Business Value WGS (GeneDx Holdings)|Total Company Value Ultragenyx Pharma (RARE)|Beam Tx - Business Value|Enterprise Value SRPT (Sarepta Therapeutics, Inc.)|Enterprise Value twistbioscience.com TWST|TXG - Total Company Value|Total Enterprise Value Intellia Therapeutics Inc|STOK: Enterprise Value|Real Price to Acquire Entire Company BioLife|Real Price to Acquire Entire Company WVE|Enterprise Value mazetx.com|Enterprise Value SION|Prime Medicine Inc (PRME) - Full Takeover Company Value|Enterprise Value TSHA (Taysha)|uniQure Pharma (QURE) - Total Enterprise Value|MGTX - Total Company Value|RGNX (regenxbio.com) - Business Value|SLDB (Solid Biosciences) - Real Price to Acquire Entire Company|Pacific Biosciences of California, Inc. - Value Adjusted for Debt and Cash|BNTC (Benitec) - Enterprise Value|Design Corp (DSGN) - Company Buyout Price|Total Company Value Rocket Pharmaceuticals (RCKT)|4dmoleculartherapeutics.com - Business Value|Enterprise Value LXEO (Lexeo Therapeutics, Inc.)|KRRO - Real Price to Acquire Entire Company|EDIT: Real Price to Acquire Entire Company|Company Buyout Price Silence Therapeutics Corp SLN|proqr.com (PRQR) - Total Company Value|Total Enterprise Value Codexis (CDXS)|SGMO (Sangamo Therapeutics, Inc.) - Enterprise Value|Real Price to Acquire Entire Company Nautilus Biotechnology Inc (NAUT)|Enterprise Value MGX|precisionbiosciences.com (DTIL) - Full Takeover Company Value|Total Company Value Generation Bio GBIO|BOLD: Business Value|Exicure Corp - Enterprise Value|IMNN (Imunon, Inc.) - Business Value|phiopharma.com (PHIO) - Total Company Value|Business Value MBIO|RNAZ (TransCode Therapeutics Inc.) - Enterprise Value|Enterprise Value Bionano|Total Company Value Applied DNA Sciences, Inc. (APDN)|BLUE - Total Enterprise Value|Enterprise Value IPA (ImmunoPrecise Antibodies Ltd.)|OMGA - Real Price to Acquire Entire Company|OMIC: Real Price to Acquire Entire Company|RGLS - Enterprise Value|SYRS: Enterprise Value|Full Takeover Company Value Telesis Bio Inc. TBIO|TCON (TRACON) - Enterprise Value|Total Enterprise Value Unity Biotechnology, Inc UBX